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Introduction: The aim of this systematic review and meta-analysis was to summarize all the existing
randomized controlled trials (RCTs) evidence and to evaluate the effects of green cardamom on lipo-
proteins, glycemic control and anthropometric parameters in healthy and/or with disease types
compared with the control.
Method: Two independent authors systematically searched online databases including EMBASE, Scopus,
PubMed, Cochrane Library, and Web of Science from inception until 30th July 2019. RCTs complying with
the following criteria were included in this meta-analysis: human trials with either cross-over design or
parallel design, trials with data on the effects of green cardamom on serum lipoproteins and glycemic
control and anthropometric parameters with standard deviation and related 95% confidence interval for
the both intervention and placebo groups. The heterogeneity among the included studies was assessed
using Cochrane's Q test and I-square (I2) statistic. Data were pooled using a random-effects model and
weighted mean difference (WMD) was considered as the overall effect size.
Result: Seven trials were included in this meta-analysis. Triglycerides were significantly reduced after
cardamom supplementation when compared with the control group. Cardamom intake from 3 small
studies resulted in a significant increase in BMI when compared with the control group. However,
cardamom supplementation did not have any significant effect on total cholesterol, LDL-cholesterol,
HDL-cholesterol, fasting plasma glucose and body weight when compared with the control group.
Conclusion: This meta-analysis demonstrated that green cardamom intake significantly reduced tri-
glycerides levels which may have played an indirect role in improved clinical symptoms in diseases with
metabolic disorders.
© 2020 European Society for Clinical Nutrition and Metabolism. Published by Elsevier Ltd. All rights
reserved.sbaghi), islampoor.eli@gmail.com (E. Eslampour), zeljko.reiner@kbc-zagreb.hr (Z. Reiner), badehnoosh@abzums.ac.ir
lahdooz), sajadmoradi9096@gmail.com (S. Moradi), dr.shahrzad.hashemi.1@gmail.com (S. Hashemi Dizaji), asemi_r@
ition and Metabolism. Published by Elsevier Ltd. All rights reserved.
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This meta-analysis demonstrated that green cardamom
intake significantly reduced plasma triglycerides levels, but
did not affect FPG, other lipids and lipoproteins and body
weight. Therefore, green cardamom intake may have
played an indirect role in improved clinical symptoms in
diseases with metabolic disorders due to its effect on tri-
glycerides levels.
1. Introduction
Herbal medicine is based upon spices and plants and although
for centuries different cultures around the world have used tradi-
tional herbal medicine to treat many diseases, recently more and
more attention has been paid on spices and plants in classical
medicine as well [1]. Green cardamom from Elettaria cardamomum
plant, known as “Queen of spice” is a member of ginger family
(Zingiberaceae) [2,3]. It has been suggested that it might have
antioxidative, anti-inflammatory, antimicrobial and anti-cancer
effects [3e6]. The antioxidative effects of cardamom are mainly
due to its polyphenols content, including flavonols (quercetin and
kaempferol), flavone (luteolin) and anthocyanidin (pelargonidin)
content [7]. It achieves antioxidant protection also by activation of
the antioxidant enzymes [8]. According to some studies green
cardamom may have beneficial effect on some lipoproteins, e.g.
HDL-cholesterol, glucose and anthropometric parameters but the
results are equivocal [9e11]. It seems that hypolipidemic effect of
green cardamommay improve insulin function by reducing glucose
and insulin levels [12].
Generally, flavonoids from green cardamom are effective in
reducing glucose absorption [13], reducing fat storage [14], acti-
vating PGC-1a [15], enhancing glucose tolerance and inhibiting
pancreatic lipase [16]. It has been also reported that 1,8-cineole,
which is a major component of the green cardamom oil, signifi-
cantly decreased fatty tissue mass and that it has vascular relaxant,
anti-inflammatory, and antioxidant properties [17]. The proposed
mechanisms include increase in antioxidant capacity and oxidation
of fats [9], enhanced insulin activity and sensitivity due to increased
glycogenesis and decreased gluconeogenesis [18], improvement in
obesity and glycemic control by increased expression and activity
of peroxisome proliferator-activated receptor gamma (PPAR-g)
[19], suppression of inflammation, nuclear factor-kappa B (NF-kB)
[7] and cholesterol synthesis [20], as well as reducing oxidative
stress [12]. However, the results of different studies are contradic-
tory. For example, the results of Aghasi et al. [21] on patients with
type 2 diabetes mellitus (T2DM) suggested that 3 g/day of green
cardamom intake during 10 weeks, showed no significant changes
in total cholesterol, LDL-cholesterol and HDL-cholesterol levels
between the intervention and placebo groups. However, in another
study by Azimi et al. [22], intake of 3 g/day of cardamom for 8
weeks in patients with T2DM resulted in a significant lipid-
lowering effect on total cholesterol and LDL-cholesterol as well as
increasing effect on HDL-cholesterol levels, but no significant
change were observed in glycemic control, oxidative stress,
inflammation and anthropometric parameters.
Daneshi-Maskooni et al. [23,24] demonstrated that 3 g/day of
green cardamom during 3 months significantly decreased tri-
glycerides, LDL-cholesterol and homeostatic model assessment for
insulin resistance (HOMA-IR) score, and increased HDL-cholesterol,
but did not have a significant effect on fasting plasma glucose
(FPG), total cholesterol, body weight and body mass index (BMI) inoverweight or obese patients with non-alcoholic fatty liver disease.
Yaghooblou et al. [10] found that 3 g/day of green cardamom for 2
months in overweight and obese pre-diabetic women increased
insulin sensitivity, and reduced total cholesterol and LDL-
cholesterol. Since there is no meta-analysis analyzing the effects of
green cardamom supplementation on serum lipoproteins, glycemic
control and anthropometric parameters, this meta-analysis was
performed to summarize all the existing randomized controlled
trials (RCTs) evidence and to evaluate the effects of green cardamom
on lipoproteins, glycemic control and anthropometric parameters in
healthy and/or with disease types compared with the control.
2. Methods
2.1. Search and studies selection strategies
Scientific international databases, including EMBASE, Scopus,
Cochrane Library, Web of Science and PubMed were searched for
relevant studies published from inception until 30th July 2019. A
search strategy was developed using the following MeSH and text
keywords; “Intervention” OR “Cardamom” OR “cardamom” OR
“cardamom” OR “cardamomum” OR “Intervention Study” OR
“Intervention Studies” OR “controlled trial” OR “randomized” OR
“random” OR “randomly” OR “placebo” OR “assignment” OR
“clinical trial” OR “Trial” OR “assignment” OR “randomized
controlled trial” OR “randomized clinical trial” OR “RCT” OR “blin-
ded” OR “double blind” OR “double blinded” OR “clinical trial” OR
“trials” OR “Pragmatic Clinical Trial” OR “Cross-Over Studies” OR
“Cross-Over” OR “Cross-Over Study” OR “parallel” OR “parallel
study” OR “parallel trial” AND outcomes ["triglycerides (TG) " OR
“total-cholesterol (TC)" OR “LDL-cholesterol” OR “LDL-C00 OR “HDL-
cholesterol” OR “HDL-C00 OR “fasting plasma glucose (FPG)" OR
“body weight” OR “BMI”. Search was confined to human clinical
RCTs and those published in English. To avoid missing reports, we
manually reviewed the reference list of articles and previous re-
view studies.
2.2. Inclusion and exclusion criteria
Randomized controlled trials complying with the following
criteria were included in this meta-analysis: human trials in
healthy and/or with disease types, either cross-over design or
parallel design, both female andmale, trials with data on the effects
of green cardamom on serum lipoproteins and glycemic control
and anthropometric parameters with standard deviation (SD) and
related 95% confidence interval (CI) for the both intervention and
placebo groups) with a duration of equal or more than eight weeks.
Other studies such as animal experiments, in vitro studies, case
reports, observational studies, trials without a control group, and
studies that did not achieve the least quality score were excluded
from this meta-analysis. This scale is a 5-point scale for measuring
the quality of randomized trials. In this measuring scale, studies
that obtain at least 3 or more score are assessed as high quality [16].
2.3. Data extraction and quality assessment
Two independent authors (OA and EE) screened the articles
based on the eligibility criteria. As the first step the titles and ab-
stracts of studies were reviewed. Then, the full-text of relevant
studies was assessed to ascertain the suitability of a study for the
meta-analysis. Any disagreement was resolved by the judgment of
the third author (ZA).
Following data were taken from selected studies: the first au-
thors’ name, study location, year of publication, sample size, age,
study design, dosage of green cardamom, duration of the study,
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cemic control and anthropometric parameters in each intervention
group. The quality of the selected RCTs was independently assessed
by the same authors using the Cochrane Collaboration risk of bias
tool based on the following criteria: “randomization generation,
allocation concealment, blinding of participants and outcome as-
sessors, incomplete outcome data, and selective outcome report-
ing, and other sources of bias” [25].
2.4. Data synthesis and statistical analysis
The effects of green cardamom consumption on the changes of
the following parameters were calculated: 1) FPG, 2) triglycerides,
3) total cholesterol, 4) LDL-cholesterol, 5) HDL-cholesterol, 6) body
weight and 7) BMI. Weighted mean difference (WMD) with 95% CI
was used for pooling data to determine the effect sizes. The changeFig. 1. Flowchart of the study selection for inclusionscore approach was used to calculate the effect size of green
cardamom intake on the analyzed parameters. The random-effect
model was used to report the pooled effect sizes using 95% CI. To
calculate the SD changes, the following formula was used:
SD ¼ square root [(SD pre-treatment)2 (SD posttreatment)2 -
(2R  SD pre-treatment  SD post-treatment)], correlation coeffi-
cient (R-value) was considered 0.8 [26]. When an SEM or SE was
reported instead of SD, the SD was calculated based on the
following formula: SD¼ SEM√n (n¼ sample size in each group).
2.5. Heterogeneity and publication bias
Heterogeneity of included studies was assessed using
Cochrane's Q test (with significant P-value <0.1) and I-square test
(I2 greater than 50 percent showing significant heterogeneity). The
funnel plot, as well as the Beggs's and Egger's regression tests wasin the systematic reviews and meta-Analyses.
Table 1
Characteristics of included studies.
Studies Publication year Study
design
Country Participants Sample size
(intervention/
control)
Sex
(intervention/
control)
Duration
(Week/Month)
BMI (kg/m2)
(intervention/
control)
Age (years)
(intervention/
control)
Intervention/control group
Aghasi et al. [21] 2019 R/DB/PC Iran Overweight or
obese patients with
type 2 diabetic
41/42 Male/Female
(53%/47%)
10 W 29.06/29.1 53.9/53.3 Intervention group:
6 capsule contained 0.5 g of
whole green cardamom
powder (3000 mg)
Placebo:
6 capsule contained 0.5 g rusk
powder (3000 mg)
Kazemi et al. [27] 2017 R/DB/PC Iran Overweight or
obese patients with
pre-diabetic
women
40/40 Female 8 W 29.7/29.3 30e70 Intervention group:
3 capsule contained 1 g of
whole green cardamom
powder (3000 mg)
Placebo:
3 capsule with similar in shape,
size, and appearance
Azimi et al. [22] 2014 R/SB/PC Iran Patients with type 2
diabetic
42/39 Male/Female
(39.5%/60.5%)
8 W 28.96/28.4 51.59/53.64 Intervention group:
3 g dried powder from
cardamom (3000 mg)
Placebo: consumed three
glasses of tea without any
spices
Daneshi-Maskoon et al. [23] 2018 R/DB/PC Iran Overweight or
obese patients with
non-alcoholic fatty
liver disease
43/44 Male/Female
(62%/38%)
12 M 30.5/30.7 45.5/45 Intervention group:
6 capsule contained 0.5 g of
green cardamom (3000 mg)
Placebo:
6 capsule with similar in shape
Daneshi-Maskoon et al. [24] 2019 R/DB/PC Iran Overweight or
obese patients with
non-alcoholic fatty
liver disease
43/44 Male/Female
(62%/38%)
12 M 25e35 30e60 Intervention group:
6 capsule contained 0.5 g of
green cardamom (3000 mg)
Placebo:
6 similar capsule
Yaghooblou et al. [10] 2017 R/DB/PC Iran Overweight or
obese patients with
pre-diabetic
women
40/40 Female 8 W 25e39.9 48.3/47.5 Intervention group:
3 capsule contained 1 g of
whole green cardamom
powder (3000 mg) placebo:
3 capsule contained 1g rusk
powder (3000 mg)
Verma et al. [28] 2012 PC India Patients with
ischemic heart
disease
15/15 Male 12 W NR 5e70 Intervention group:
4 capsule contained 0.75 g of
whole green cardamom
powder (3000 mg)
Placebo:
4 capsule contained 0.75 lactose
powder (3000 mg)
R: randomized, DB: double blind, SB: single blind, PC: placebo-control, NR: not-reported.
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Table 2
The effects of cardamom on glycemic control, serum lipids and anthropometric measurements.
Variables Number of effect sizes Weighted mean difference 95% CI P- value Heterogeneity
I2 (%) P- value heterogeneity
FPG (mg/dl) 4 0.98 2.45, 0.49 0.191 0.0% 0.592
TC (mg/dl) 5 7.51 20.37, 5.36 0.253 96.5% <0.001
LDL-C (mg/dl) 5 6.58 16.51, 3.36 0.194 95.4% <0.001
TG (mg/dl) 5 14.25 28.34, 0.17 0.047 98.2% <0.001
HDL-C (mg/dl) 5 1.31 0.28, 2.89 0.106 95.6% <0.001
Body weight (kg) 3 0.14 0.19, 0.46 0.406 0.0% 0.845
BMI (kg/m2) 4 0.07 0.01, 0.12 0.024 0.0% 0.516
FPG, fasting plasma glucose; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; BMI, body mass
index.
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Corp., College Station, TX) and Review Manager 5.3 (Cochrane
Collaboration, Oxford, UK) were applied for data analysis.3. Results
3.1. Study selection
We identified 212 studies; 78 duplicate articles were
detected and removed. After screening, 134 articles based onFig. 2. AeG.Meta-analysis metabolic profiles and anthropometric measurements weighted
C) total cholesterol (mg/dl), D) Low-density lipoprotein-cholesterol (mg/dl), E) High-density
cardamom and control groups.title and abstract, 124 articles were removed because they
were either performed on animals, or were review articles or
were unrelated studies. 3 publications were excluded based on
low full-text quality assessment. Finally, 7 articles
[10,21e24,27,28] were included in our systematic review and
meta-analysis. Of these, 5 trials [10,21,22,24,28] reported the
effect of cardamom on serum lipoproteins, 4 trials
[10,21,22,24] on FPG, 3 articles [22,23,27] on body weight and
4 studies [21e23,27] on BMI. Flowchart of study selection
summarized in Fig. 1.mean difference estimates for A) fasting blood glucose (mg/dl), B) triglycerides (mg/dl),
lipoprotein-cholesterol (mg/dl), F) body weight (kg) G) Body mass index (kg/m2) in the
Fig. 2. (continued).
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The general characteristics of eligible studies are outlined in
Table 1. These articles were published between 2012 and 2019 and
were performed in Iran [10,21e24,27] and India [28]. Study dura-
tion ranged from 2 to 3 months. The dosage in all the included
studies [10,21e24,27,28] was 3000 mg/day. Study design in all
studies [10,21e24,27,28] was parallel. Five studies [21e24,28] were
performed on subjects of both sexes and two studies [10,27] were
done on women. Sample size in eligible trials ranged from 30 [28]
to 87 [23,24]. In total, 528 subjects were enrolled in these trials, of
which 264 individuals were randomized to the cardamom group
and 264 subjects to the control group. Mean age of the participants
ranged from 30 to 70 years and the mean baseline BMI varied from
25 to 39.9 kg/m2. Participants in these studies were patients with
pre-diabetes [10,27], T2DM [21,22], non-alcoholic fatty liver disease
[23,24] and ischemic heart disease [28].3.3. Effect of cardamom on serum lipoproteins, glycemic control
and anthropometric indices
Five included studies with 361 participants analyzed the ef-
fects of cardamom supplementation on triglycerides, total
cholesterol, LDL-cholesterol and HDL-cholesterol levels. Pooling
their data based on random-effects model, we found thattriglycerides were significantly reduced after cardamom supple-
mentation (WMD: 14.25 mg/dL, 95% CI; 28.34 to 0.17,
P ¼ 0.047) when compared with the control group (Table 2 &
Fig. 2B). However, cardamom supplementation did not have any
significant effects on total cholesterol (WMD: 7.51 mg/dL, 95%
CI; 20.37 to 5.36, P ¼ 0.253) (Table 2 & Fig. 2C), LDL-cholesterol
(WMD: 6.58 mg/dL, 95% CI; 16.51 to 3.36, P ¼ 0.194) (Table 2 &
Fig. 2D) and HDL-cholesterol levels (WMD: 1.31 mg/dL, 95%
CI; 0.28 to 2.89, P ¼ 0.106) (Table 2 & Fig. 2E). However, there
was significant heterogeneity between studies, we conducted
stratified analysis to explore potential sources of heterogeneity.
The results of the sub-group analysis have demonstrated that
cardamom intake had significant effect on reducing TG levels in
studies with duration 12 weeks (WMD: 19.55 mg/dL, 95%
CI; 24.25 to 14.86, P < 0.001) and non-diabetic patients
(WMD: 19.00 mg/dL, 95% CI; 23.56 to 14.44, P < 0.001). In
addition, cardamom intake had a significant impact on reducing
TC (WMD: 12.86 mg/dL, 95% CI; 25.47 to 0.25, P ¼ 0.046) and
LDL-cholesterol levels (WMD: 11.50 mg/dL, 95% CI; 21.71
to 1.28, P ¼ 0.027) in non-diabetic patients. On the other hand,
subgroup analysis showed that long-term intervention (12
weeks) increased HDL-cholesterol levels (Table 3).
The impact of cardamom supplementation on FPG was assessed
in 4 studies which included 331 participants. The pooled estimates
showed that there was no significant effect of cardamom on FPG,
Table 3
Subgroup analyses of cardamom intake on lipid profiles.
NO WMD (95%CI) P within group P heterogeneity I2
Subgroup analyses of cardamom intake on TG levels
Trial duration (week)
<12 3 9.41 (31.46, 12.63) 0.403 <0.001 99.1%
12 2 19.55 (24.25, 14.86) <0.001 0.504 0.0%
Diabetes status
T2DM 2 9.30 (35.74, 17.13) 0.491 <0.001 99.5%
Non-diabetic 3 19.00 (23.56, 14.44) <0.001 0.497 0.0%
Subgroup analyses of cardamom intake on TC levels
Baseline serum TC (mg/dl)
<200 3 1.76 (10.33, 6.79) 0.686 0.013 77.2%
>200 2 14.84 (32.39, 2.69) 0.097 0.001 90.5%
Trial duration (week)
<12 3 1.76 (10.33, 6.79) 0.686 0.013 77.2%
12 2 14.84 (32.39, 2.69) 0.097 0.001 90.5%
Diabetes status
T2DM 2 0.65 (8.32, 9.63) 0.886 0.039 76.5%
Non-diabetic 3 12.86 (25.47, 0.25) 0.046 0.001 85.2%
Subgroup analyses of cardamom intake on LDL-C levels
Baseline serum LDL-C (mg/dl)
>100 1 2.80 (7.51, 1.91) 0.244 e e
<100 4 7.54 (19.38, 4.29) 0.212 <0.001 97.4%
Trial duration (week)
<12 3 1.58 (8.41, 5.24) 0.650 <0.001 90.2%
12 2 13.82 (29.32, 1.68) 0.081 <0.001 94.6%
Diabetes status
T2DM 2 0.88 (5.47, 7.25) 0.785 0.008 85.7%
Non-diabetic 3 11.50 (21.71, 1.28) 0.027 <0.001 91.5%
Subgroup analyses of cardamom intake on HDL-C levels
Baseline serum HDL-C (mg/dl)
<50 3 3.69 (2.43, 9.81) 0.238 0.005 81.1%
>50 1 1.56 (5.42, 2.30) 0.428 e e
Trial duration (week)
<12 3 0.34 (2.93, 2.23) 0.793 0.705 0.0%
12 1 8.00 (5.23, 10.76) <0.001 e e
Diabetes status
T2DM 2 1.40 (5.07, 2.26) 0.452 0.804 0.0%
Non-diabetic 2 4.45 (2.70, 11.60) 0.223 0.002 89.8%
CI, confidence interval; TG, triglycerides; TC, total cholesterols; LDL-C, Low-density lipoprotein cholesterol; HDL-C, High-density lipoprotein cholesterol; T2DM, type 2 dia-
betes mellitus; WMD, weighted mean differences.
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CI; 2.45 to 0.49, P ¼ 0.191) (Table 2 & Fig. 2A).
Pooling effect sizes from 3 trials which included 248 patients,
we found that cardamom administration had no significant effect
on body weight when compared with the control group (WMD:
0.14 kg, 95% CI; 0.19 to 0.46, P ¼ 0.406) (Table 2 & Fig. 2F). Four
trials with 331 subjects, reported an increasing effect of cardamom
on BMI. Pooled results from fix-effect model demonstrated a sig-
nificant increasing effect of cardamom on BMI. Cardamom inter-
vention from 3 small studies resulted in a significant increase in
BMIwhen comparedwith controlled group (WMD: 0.07 kg/m2, 95%
CI; 0.01 to 0.12, P ¼ 0.024) (Table 2 & Fig. 2G).
3.4. Publication bias
Publication bias assessment was done based on begg's regres-
sion tests and visual inspection of funnel plot (Fig. 3AeG). Results
demonstrated no evidence of bias related with triglycerides
(P ¼ 0.806), total cholesterol (P ¼ 0.806), LDL-cholesterol
(P ¼ 0.462), HDL-cholesterol (P ¼ 1.000), FPG (P ¼ 1.000), body
weight (P ¼ 0.296) and BMI (P ¼ 1.000).
3.5. Quality assessment
The quality of the studies was evaluated on the basis of the
Cochrane tool, and its results are summarized in Table 4. Most
studies indicated adequate quality for key factors [10,21e24,27].One had fair quality for random Sequence Generation, allocation
concealment and other sources of bias [28], and in related with
blinding of participants personnel two studies had low quality
[22,28].
4. Discussion
This is the first meta-analysis of RCTs evaluating the effects of
green cardamom on FPG, serum lipoproteins and anthropometric
parameters. This meta-analysis demonstrated that green
cardamom intake significantly reduced triglycerides levels and
significantly increased BMI, but did not have a significant effect on
FPG, other lipids and lipoproteins and body weight. Although BMI
statistically significant, it marginal improvement.
Today, a growing interest exists in patients with metabolic dis-
orders for using dietary supplements in order to control insulin
resistance and dyslipidemia [29]. In our meta-analysis of RCTs,
green cardamom intake significantly reduced triglycerides levels
and significantly increased BMI, but did not have a significant effect
on FPG, other lipids and lipoproteins and body weight. Overall,
pooling information from all qualified RCTs, provides more precise
and powerful evidence than those from the individual studies.
However, these studies are heterogeneous with respect to study
duration, green cardamom dose, the characteristics of participants,
sampling method, age ranges, differences between intervention
and control groups, allocation concealment, cross-over design or
parallel design, dietary intake of participants, and the assessment
Fig. 3. AeG. Funnel plot representing publication bias in the studies reporting the impact of cardamom intake on A) fasting blood glucose, B) triglycerides, C) total cholesterol, D)
Low-density lipoprotein-cholesterol, E) High-density lipoprotein-cholesterol, F) body weight G) Body mass index.
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Table 4
Risk of bias assessment of the studies included in this meta-analysis.
Studies Random
Sequence
Generation
Allocation
concealment
Selective
outcome
reporting
Other
sources
of bias
Blinding
of participants
personnel
Blinding
of outcome
assessors
Incomplete
outcome data
Aghasi et al. [21] L L L L L H L
Kazemi et al. [27] L U L L L H L
Azimi et al. [22] L U L L H H L
Daneshi-Maskoon et al. [23] L L L L L U L
Daneshi-Maskoon et al. [24] L L L L L H L
Yaghooblou et al. [10] L U L L L U L
Verma et al. [28] H H L H H H L
Abbreviation; L: low-risk of bias, H: high-risk of bias, U: unclear-risk of bias.
O. Asbaghi et al. / Clinical Nutrition ESPEN 37 (2020) 24e3332method of BMI status/weight change. In particular, the wide vari-
ation in the amount and formulation of green cardamom may be
the most important contributor to the heterogeneity seen in our
results. In a study by Aghasi et al. [21], green cardamom at a dosage
3 g/day during 10 weeks decreased insulin levels, HbA1c levels,
HOMA-IR score and triglycerides levels by increase in sirtuin-
1(SIRT1) levels in patients with T2DM. Yaghooblou et al. [10]
showed that 3 g/day of cardamom supplementation to pre-diabetic
subjects for 8 weeks was associated with an improvement in in-
sulin sensitivity and decreased total cholesterol and LDL-
cholesterol concentrations. However, these findings were not sig-
nificant when compared with the placebo group. In patients with
ischemic heart disease cardamom consumption significantly
reduced serum total cholesterol, LDL-cholesterol and triglycerides
levels [30]. Another study in patients with T2DM showed that
consumption of 3 glasses of black tea plus 3 g cardamom daily
improved total cholesterol, triglycerides, LDL-cholesterol and HDL-
cholesterol levels when compared with the control group [22]. The
beneficial effects were seen following the intake of 500mg of green
cardamom three times a day for 12 weeks in overweight or obese
NAFLD patients decreasing FPG, insulin, triglycerides, and LDL-
cholesterol levels, increasing HDL-cholesterol and decreasing the
grade of fatty liver [24].
Cardamom has a high content of polyphenolic compounds,
including kaempferol, luteolin, quercetin, gallic acid, pelargonidin,
caffeic acid and limonene [31]. The underlying mechanism of
beneficial effects of green cardamom on serum triglycerides levels
may be related to improvement in insulin resistance [32]. It was
shown that insulin resistance is directly associated with plasma
triglycerides concentrations [33]. Circulating lipoprotein lipase, an
enzyme which is regulated by insulin, hydrolyzes triglycerides in
lipoproteins. This enzyme is inhibited in subjects with insulin-
resistance, which has hypertriglyceridemia as a consequence [34].
Another possible mechanism of green cardamom effects on serum
lipoproteins may be by its effects on PPARs. SIRT1 is associated with
lipid metabolism by the activation of PPAR-g [35]. It is very difficult
to explain howgreen cardamom could increase BMIwithout having
any significant effect on body weight.
The current meta-analysis is among rare studies that summarize
findings from earlier studies on the effects of green cardamom
intake on lipoproteins, glycemic control and anthropometric pa-
rameters. Therefore it is important to consider some imitations of
this meta-analysis when interpreting the results and producing
conclusions. This study has some limitations. One of the most
important is that patients in the included studies had different
diseases such as pre-diabetes, T2DM, non-alcoholic fatty liver dis-
ease and ischemic heart disease which might have an influence on
the results. Moreover, due to the heterogeneity between studies,
evident from the variations in duration of green cardamom intake,
the dosage and frequency of green cardamom used, results should
be interpreted with caution. Green cardamom in different formsand by different methods were obtained that may have different
effects on metabolic profiles and anthropometric parameters. The
number of studies and sample size of participant's study that finally
entered to the meta-analysis was low. Daneshi-Maskoon et al. [24]
and Yaghooblou et al. [10] have significantly different BMI and age
distribution. This could have greatly affected the results. Due to the
small number of studies, we could not re-analyze without these
two studies. So further studies are needed to reach a definitive
conclusion.
5. Conclusions
This meta-analysis demonstrated that green cardamom intake
significantly reduced plasma triglycerides levels and significantly
increased BMI, but did not affect FPG, other lipids and lipoproteins
and body weight. Although BMI statistically significant, it marginal
improvement. Therefore, green cardamom intake may have played
an indirect role in improved clinical symptoms in diseases with
metabolic disorders due to its effect on triglycerides levels.
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